TSX:DML

Uranium Boom or Bust? Denison Mines (DNN) Stock Soars on Nuclear Revival – Full 2025 Analysis

Denison Mines (DNN) Q3 2025 Earnings Today: What to Watch as Wheeler River Faces Judicial Review

Denison Mines is set to report Q3 2025 results today after confirming a legal challenge from Peter Ballantyne Cree Nation over its Wheeler River uranium project. Shares crossed above the 200-day moving average on the TSX this week. Analysts expect around CAD 1.10 million in revenue and a loss per share of about CAD 0.024 for the quarter.

6 November 2025

Earnings Reports·NYSEA:DNN·TSX:DML

Uranium Boom or Bust? Denison Mines (DNN) Stock Soars on Nuclear Revival – Full 2025 Analysis

Denison Mines shares traded near $2.80 on Nov. 4 after a legal challenge by the Peter Ballantyne Cree Nation threatened to delay its flagship Wheeler River uranium project. The stock remains up 54% year-to-date, despite recent volatility. Wall Street analysts maintain mostly Buy ratings, with target prices around $3.00–3.40. Denison’s Q3 earnings are due Nov. 6.

4 November 2025

Stock Market·TSX:DML

Denison Mines Stock Skyrockets on Uranium Boom – Is the Rally Just Beginning?

Denison Mines shares have more than doubled in 2025, recently hitting multi-year highs near $3.30 amid surging uranium prices and renewed production at its McClean Lake venture. The company’s flagship Wheeler River project in Saskatchewan awaits final federal approval, with hearings set for December. Denison raised $345 million in August and now holds a market cap near $2.7 billion. Institutional ownership has climbed to about 37%.

27 October 2025

NYSEA:DNN·Stock Market·TSX:DML

Previous 1 2

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).